Nano-engineered Antibiotic Formulation That Targets Chronic MRSA Infection

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Antibiotic resistance, particularly from methicillin-resistant Staphylococcus aureus (MRSA) and Extended-Spectrum Beta-Lactamase (ESBL)-producing bacteria, poses a significant threat in healthcare settings.
• The emergence and spread of these resistant strains necessitate novel therapeutic strategies to improve treatment outcomes.

Purpose of the Study:

• To investigate the efficacy of liposome-encapsulated antibiotics against key antibiotic-resistant bacteria, including MRSA and ESBL-producers.
• To evaluate the characterization and antimicrobial activity of various antibiotics encapsulated within liposomes.

Main Methods:

• MRSA isolates were tested for resistance to common antibiotics on Mueller-Hinton agar.
• Liposomes were formulated and characterized for encapsulation efficiency and integrity using UV-visible spectrophotometry.
• Antimicrobial efficacy of encapsulated antibiotics (ciprofloxacin, amikacin, cloxacillin, vancomycin) was assessed against a panel of bacteria, including E. coli, S. aureus, A. baumannii, K. pneumoniae, and MRSA.

Main Results:

• MRSA isolates demonstrated complete resistance to ampicillin, ciprofloxacin, amoxicillin, and amoxicillin-clavulanic acid.
• Liposomal encapsulation significantly enhanced antimicrobial activity against tested bacterial strains.
• Ciprofloxacin-loaded liposomes achieved high entrapment efficiency (76% after 24 hours).
• Liposome-encapsulated aminoglycosides showed particular promise against Acinetobacter baumannii in localized infections.

Conclusions:

• Liposomal antibiotic formulations offer enhanced antimicrobial efficacy compared to free drugs.
• This approach holds significant potential for treating severe systemic and topical infections caused by antibiotic-resistant bacteria.
• Liposomal delivery may improve therapeutic effectiveness and minimize adverse effects, presenting a viable strategy against resistant infections.